Plain-English translation of NCT07111507 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called for men with advanced prostate cancer that has spread to other parts of the body and either came back after treatment or didn't respond to it. The study focuses specifically on cancers that have a marker called DLL3. Researchers want to see if this medication can help control the cancer.
Advanced prostate cancer that stops responding to standard treatments is difficult to manage, and patients need new options. This medication works differently than current treatments, and early research suggests it may help certain prostate cancers that have specific markers.
You likely qualify if…
You likely don't qualify if…
You would receive the medication through regular visits to the cancer center. The first cycle involves a lower starting dose, then the full dose on days 8 and 15. After that, you receive the medication on days 1 and 15 of each cycle. The study will monitor you with blood tests and imaging scans to see how you're responding to the treatment. The exact length of participation depends on how well the medication works and whether you experience side effects.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States